NC
MRTX

NewSquare Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

NewSquare Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$181 – 932
2023
Q2 		$181 Hold
5
– – ﹤0.01% 765
2023
Q1 		$186 Hold
5
– – ﹤0.01% 796
2022
Q4 		$227 Buy
+5
New +$324 ﹤0.01% 722

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewSquare Capital's MRTX Position: Q3 2023 in Review

NewSquare Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 5 shares — an estimated $181 sold.

NewSquare Capital first reported a position in MRTX in Q4 2022 and held it in 3 quarters. The position peaked at $227 in Q4 2022. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • NewSquare Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 5 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $181.
  • NewSquare Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $227 in Q4 2022.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.